Wisman Peter Paul, Teraa Martin, de Borst Gert Jan, Verhaar Marianne C, Roest Mark, Moll Frans L
Department of Vascular Surgery, University Medical Center Utrecht, Utrecht, 3584CX, The Netherlands; Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, 3584CX, The Netherlands.
Department of Vascular Surgery, University Medical Center Utrecht, Utrecht, 3584CX, The Netherlands; Department of Nephrology & Hypertension, University Medical Center Utrecht, Utrecht, 3584CX, The Netherlands.
PLoS One. 2015 Jul 6;10(7):e0131356. doi: 10.1371/journal.pone.0131356. eCollection 2015.
Patients with critical limb ischemia (CLI) have a high risk to develop cardiovascular events (CVE). We hypothesized that in CLI patients platelets would display increased baseline activation and reactivity.
We investigated baseline platelet activation and platelet reactivity in patients with CLI.
PATIENTS/METHODS: In this study baseline platelet activation and platelet reactivity in response to stimulation of all major platelet activation pathways were determined in 20 CLI patients (11 using aspirin and 9 using vitamin K-antagonists) included in the Juventas-trial (clinicaltrials.gov NCT00371371) and in 17 healthy controls. Platelet activation was quantified with flow cytometric measurement of platelet P-selectin expression and fibrinogen binding.
CLI patients not using aspirin showed higher baseline platelet activation compared to healthy controls. Maximal reactivity to stimulation of the collagen and thrombin activation pathway was decreased in CLI patients compared to healthy controls. In line, attenuated platelet reactivity to stimulation of multiple activation pathways was associated with several traditional risk factors for cardiovascular disease.
Baseline platelet activation was increased in CLI patients, whereas the reactivity of circulating platelets to several stimulatory agents is decreased. Reactivity of platelets was inversely correlated with cardiovascular risk factors.
严重肢体缺血(CLI)患者发生心血管事件(CVE)的风险很高。我们假设CLI患者的血小板会表现出更高的基线激活和反应性。
我们研究了CLI患者的基线血小板激活和血小板反应性。
患者/方法:在这项研究中,对纳入Juventas试验(clinicaltrials.gov NCT00371371)的20例CLI患者(11例使用阿司匹林,9例使用维生素K拮抗剂)和17例健康对照者,测定了对所有主要血小板激活途径刺激的基线血小板激活和血小板反应性。通过流式细胞术测量血小板P-选择素表达和纤维蛋白原结合来定量血小板激活。
未使用阿司匹林的CLI患者与健康对照相比,基线血小板激活更高。与健康对照相比,CLI患者对胶原和凝血酶激活途径刺激的最大反应性降低。同样,循环血小板对多种激活途径刺激的反应性减弱与几种传统心血管疾病危险因素相关。
CLI患者的基线血小板激活增加,而循环血小板对几种刺激剂的反应性降低。血小板反应性与心血管危险因素呈负相关。